好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Profile and Prognosis of Youth with Status Migrainosus: Results From an Observational Study
Headache
S1 - Headache 1 (2:24 PM-2:36 PM)
008

Data on the clinical characteristics of children and adolescents with status migrainosus are sparse and little is known about the prognosis of this population.

To characterize the clinical features of a large sample of children, adolescents and young adults with a history of status migrainosus and to describe their short-term prognosis.

Patients from the Cincinnati Children’s Hospital Headache Center were included if they had a diagnosis of migraine and data available for a 1-3 month follow-up interval. Data extracted from the initial interval visit (visit A) included: age, sex, race, migraine diagnosis, status migrainosus (SM) history, chronic migraine, medication overuse headache (MOH), BMI, headache frequency, headache severity, disability, allodynia and lifestyle habits: caffeine intake, meal skipping, sleep duration, exercise frequency and fluid intake. Data extracted from the initial consultation visit included: months with headache at initial consultation visit, patient endorsing “feeling depressed” and anxiety symptoms. Headache frequency and visit type were also measured at the second visit (visit B) in the follow-up interval.

A total of 5,316 youth with migraine were included and 559 (10.5%) had a history of SM. In the multivariate logistic regression model, predictors significantly associated with SM were: older age, female, White, migraine with aura, MOH, higher headache severity, higher disability and months with headache at initial consultation. Patients with a history of SM were more likely to experience an increase in 4 or more headache days per month at follow-up: 15.2% as compared to 11.1% of those without SM, c2 (1, n=5,316)=8.172, p=0.0043.

Youth with status migrainosus represent a distinct subgroup of the migraine population and have an unfavorable short-term prognosis.
Authors/Disclosures
Serena Orr, MD (University of Calgary)
PRESENTER
The institution of Dr. Orr has received research support from Alberta Children's Hospital Research Institute. The institution of Dr. Orr has received research support from Canadian Institutes of Health Research. The institution of Dr. Orr has received research support from Department of Pediatrics, University of Calgary. The institution of Dr. Orr has received research support from American Headache Society. Dr. Orr has received publishing royalties from a publication relating to health care. Dr. Orr has a non-compensated relationship as a associate editor with Headache: The Journal of Head and Face Pain that is relevant to AAN interests or activities. Dr. Orr has a non-compensated relationship as a editorial board member with Neurology that is relevant to AAN interests or activities. Dr. Orr has a non-compensated relationship as a editorial board member with American Migraine Foundation that is relevant to AAN interests or activities.
Abigail Turner No disclosure on file
Marielle K. Samaha, MD, FAHS, FAAN, FAAN (Cincinnati Children's Hosp Medl Ctr) Dr. Samaha has received personal compensation in the range of $500-$4,999 for serving as a Consultant for theranica. Dr. Samaha has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for AAN . The institution of Dr. Samaha has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for AAP.
No disclosure on file
Hope M. O'Brien, MD, MBA, FAAN (Headache Center of Hope) The institution of Dr. O'Brien has received personal compensation in the range of $0-$499 for serving as a Consultant for Guidepoint. The institution of Dr. O'Brien has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. The institution of Dr. O'Brien has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Pfizer. The institution of Dr. O'Brien has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. An immediate family member of Dr. O'Brien has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Astra Zenica. The institution of Dr. O'Brien has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. O'Brien has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eli Lilly. The institution of Dr. O'Brien has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Scilex. The institution of Dr. O'Brien has received research support from Abbvie. The institution of Dr. O'Brien has received research support from Eli Lilly. Dr. O'Brien has received publishing royalties from a publication relating to health care. Dr. O'Brien has a non-compensated relationship as a Accreditation Council Member with UCNS that is relevant to AAN interests or activities.
Joanne Kacperski, MD (Cincinnati Children's Hospital) Dr. Kacperski has nothing to disclose.
No disclosure on file
Shannon White, NP (Houston Methodist Hospital) No disclosure on file
No disclosure on file
No disclosure on file
Scott Powers, PhD (Cincinnati Children's Hospital) Scott Powers, PhD has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Theranica. The institution of Scott Powers, PhD has received research support from NIH. The institution of Scott Powers, PhD has received research support from PCORI. Scott Powers, PhD has a non-compensated relationship as a Associate Editor with The Journal HEADACHE that is relevant to AAN interests or activities. Scott Powers, PhD has a non-compensated relationship as a Member Board of Directors with American Headache Society that is relevant to AAN interests or activities.
Andrew D. Hershey, MD, PhD, FAAN, FAHS, FAAN The institution of Dr. Hershey has received personal compensation in the range of $0-$499 for serving as a Consultant for Amgen. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Upsher-Smith. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. The institution of Dr. Hershey has received research support from Amgen. The institution of Dr. Hershey has received research support from NIH, NINDS. The institution of Dr. Hershey has received research support from Bioahaven. The institution of Dr. Hershey has received research support from Upsher-Smith. Dr. Hershey has received publishing royalties from a publication relating to health care.